Usana Health Sciences Inc. (USNA)

$46.26

-0.52

(-1.11%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $45.81
    $46.95
    $46.26
    downward going graph

    0.97%

    Downside

    Day's Volatility :2.43%

    Upside

    1.47%

    downward going graph
  • $41.45
    $69.60
    $46.26
    downward going graph

    10.4%

    Downside

    52 Weeks Volatility :40.45%

    Upside

    33.53%

    downward going graph

Returns

PeriodUsana Health Sciences Inc.Sector (Consumer Staples)Index (Russel 2000)
3 Months
4.59%
4.9%
0.0%
6 Months
-4.4%
8.4%
0.0%
1 Year
-26.49%
3.6%
0.0%
3 Years
-54.46%
10.2%
-19.4%

Highlights

Market Capitalization
891.2M
Book Value
$26.25
Earnings Per Share (EPS)
3.21
PE Ratio
14.57
PEG Ratio
1.33
Wall Street Target Price
55.5
Profit Margin
6.88%
Operating Margin TTM
10.83%
Return On Assets TTM
9.2%
Return On Equity TTM
12.97%
Revenue TTM
900.4M
Revenue Per Share TTM
46.84
Quarterly Revenue Growth YOY
-8.3%
Gross Profit TTM
804.7M
EBITDA
103.5M
Diluted Eps TTM
3.21
Quarterly Earnings Growth YOY
-0.09
EPS Estimate Current Year
2.78
EPS Estimate Next Year
3.15
EPS Estimate Current Quarter
0.69
EPS Estimate Next Quarter
0.69

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Usana Health Sciences Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 19.97%

Current $46.26
Target $55.50

Company Financials

FY18Y/Y Change
Revenue
1.2B
↑ 13.56%
Net Income
126.2M
↑ 101.85%
Net Profit Margin
10.61%
↑ 4.64%
FY19Y/Y Change
Revenue
1.1B
↓ 10.79%
Net Income
100.5M
↓ 20.36%
Net Profit Margin
9.48%
↓ 1.13%
FY20Y/Y Change
Revenue
1.1B
↑ 6.95%
Net Income
124.7M
↑ 24.01%
Net Profit Margin
10.99%
↑ 1.51%
FY21Y/Y Change
Revenue
1.2B
↑ 4.57%
Net Income
116.5M
↓ 6.54%
Net Profit Margin
9.82%
↓ 1.17%
FY22Y/Y Change
Revenue
998.6M
↓ 15.83%
Net Income
69.4M
↓ 40.47%
Net Profit Margin
6.94%
↓ 2.88%
FY23Y/Y Change
Revenue
921.0M
↓ 7.77%
Net Income
63.8M
↓ 8.02%
Net Profit Margin
6.93%
↓ 0.01%
Q4 FY22Q/Q Change
Revenue
228.0M
↓ 2.29%
Net Income
12.8M
↓ 14.29%
Net Profit Margin
5.61%
↓ 0.79%
Q1 FY23Q/Q Change
Revenue
248.4M
↑ 8.95%
Net Income
18.4M
↑ 43.67%
Net Profit Margin
7.4%
↑ 1.79%
Q2 FY23Q/Q Change
Revenue
238.2M
↓ 4.09%
Net Income
17.3M
↓ 5.93%
Net Profit Margin
7.26%
↓ 0.14%
Q3 FY23Q/Q Change
Revenue
213.4M
↓ 10.43%
Net Income
11.3M
↓ 34.38%
Net Profit Margin
5.32%
↓ 1.94%
Q4 FY23Q/Q Change
Revenue
221.1M
↑ 3.62%
Net Income
16.8M
↑ 47.76%
Net Profit Margin
7.58%
↑ 2.26%
Q1 FY24Q/Q Change
Revenue
227.8M
↑ 3.04%
Net Income
16.5M
↓ 1.37%
Net Profit Margin
7.26%
↓ 0.32%
FY18Y/Y Change
Total Assets
554.5M
↑ 6.78%
Total Liabilities
163.3M
↑ 4.65%
FY19Y/Y Change
Total Assets
516.9M
↓ 6.77%
Total Liabilities
165.2M
↑ 1.17%
FY20Y/Y Change
Total Assets
640.9M
↑ 23.98%
Total Liabilities
199.2M
↑ 20.59%
FY21Y/Y Change
Total Assets
577.7M
↓ 9.85%
Total Liabilities
182.6M
↓ 8.34%
FY22Y/Y Change
Total Assets
596.5M
↑ 3.26%
Total Liabilities
162.1M
↓ 11.25%
FY23Y/Y Change
Total Assets
632.8M
↑ 6.07%
Total Liabilities
135.6M
↓ 16.36%
Q4 FY22Q/Q Change
Total Assets
596.5M
↑ 7.28%
Total Liabilities
162.1M
↑ 11.8%
Q1 FY23Q/Q Change
Total Assets
605.5M
↑ 1.51%
Total Liabilities
150.2M
↓ 7.34%
Q2 FY23Q/Q Change
Total Assets
602.7M
↓ 0.47%
Total Liabilities
133.9M
↓ 10.87%
Q3 FY23Q/Q Change
Total Assets
601.1M
↓ 0.25%
Total Liabilities
130.8M
↓ 2.32%
Q4 FY23Q/Q Change
Total Assets
632.8M
↑ 5.26%
Total Liabilities
135.6M
↑ 3.67%
Q1 FY24Q/Q Change
Total Assets
629.3M
↓ 0.55%
Total Liabilities
129.3M
↓ 4.62%
FY18Y/Y Change
Operating Cash Flow
152.1M
↑ 22.89%
Investing Cash Flow
-69.0M
↑ 434.82%
Financing Cash Flow
-105.3M
↑ 109.23%
FY19Y/Y Change
Operating Cash Flow
126.7M
↓ 16.69%
Investing Cash Flow
47.5M
↓ 168.83%
Financing Cash Flow
-152.1M
↑ 44.43%
FY20Y/Y Change
Operating Cash Flow
160.4M
↑ 26.57%
Investing Cash Flow
-34.0M
↓ 171.51%
Financing Cash Flow
-59.4M
↓ 60.91%
FY21Y/Y Change
Operating Cash Flow
121.2M
↓ 24.42%
Investing Cash Flow
-14.2M
↓ 58.23%
Financing Cash Flow
-181.4M
↑ 205.19%
FY22Y/Y Change
Operating Cash Flow
103.9M
↓ 14.29%
Investing Cash Flow
-12.4M
↓ 12.81%
Financing Cash Flow
-30.1M
↓ 83.41%
Q4 FY22Q/Q Change
Operating Cash Flow
40.5M
↑ 38.93%
Investing Cash Flow
-3.3M
↓ 8.3%
Financing Cash Flow
-150.0K
↑ 240.91%
Q1 FY23Q/Q Change
Operating Cash Flow
12.8M
↓ 68.28%
Investing Cash Flow
-3.4M
↑ 2.93%
Financing Cash Flow
-3.2M
↑ 2032.67%
Q2 FY23Q/Q Change
Operating Cash Flow
9.6M
↓ 25.57%
Investing Cash Flow
179.0K
↓ 105.3%
Financing Cash Flow
-55.0K
↓ 98.28%
Q3 FY23Q/Q Change
Operating Cash Flow
22.2M
↑ 132.79%
Investing Cash Flow
-1.5M
↓ 912.29%
Financing Cash Flow
-11.6M
↑ 21065.45%

Technicals Summary

Sell

Neutral

Buy

Usana Health Sciences Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Usana Health Sciences Inc.
Usana Health Sciences Inc.
1.65%
-4.4%
-26.49%
-54.46%
-26.36%
Kraft Heinz Company, The
Kraft Heinz Company, The
1.47%
-9.9%
-9.01%
-15.94%
5.18%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
7.34%
13.9%
-15.95%
-16.09%
-7.35%
Hormel Foods Corporation
Hormel Foods Corporation
4.3%
4.74%
-20.94%
-33.59%
-23.14%
General Mills, Inc.
General Mills, Inc.
-3.46%
1.9%
-15.69%
7.44%
22.72%
Kellanova
Kellanova
0.42%
8.11%
-14.42%
-10.0%
2.51%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Usana Health Sciences Inc.
Usana Health Sciences Inc.
14.57
14.57
1.33
2.78
0.13
0.09
NA
26.25
Kraft Heinz Company, The
Kraft Heinz Company, The
14.46
14.46
1.02
2.75
0.06
0.04
0.05
40.79
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
27.09
27.09
2.48
2.86
0.14
0.05
0.02
19.83
Hormel Foods Corporation
Hormel Foods Corporation
23.02
23.02
2.96
1.6
0.1
0.05
0.04
14.39
General Mills, Inc.
General Mills, Inc.
15.2
15.2
1.98
4.5
0.25
0.07
0.04
16.81
Kellanova
Kellanova
24.93
24.93
2.93
3.62
0.21
0.05
0.04
9.24
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Usana Health Sciences Inc.
Usana Health Sciences Inc.
Sell
$891.2M
-26.36%
14.57
6.88%
Kraft Heinz Company, The
Kraft Heinz Company, The
Buy
$40.2B
5.18%
14.46
10.62%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
Hold
$20.0B
-7.35%
27.09
11.07%
Hormel Foods Corporation
Hormel Foods Corporation
Hold
$17.7B
-23.14%
23.02
6.37%
General Mills, Inc.
General Mills, Inc.
Hold
$36.6B
22.72%
15.2
12.57%
Kellanova
Kellanova
Hold
$20.1B
2.51%
24.93
7.09%

Insights on Usana Health Sciences Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 213.36M → 227.8M (in $), with an average increase of 3.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 16.76M → 16.53M (in $), with an average decrease of 1.4% per quarter

  • Vs KHC

    In the last 1 year, Usana Health Sciences Inc. has experienced a drawdown of -26.5%, however Kraft Heinz Company, The resisted the overall trend and outperformed by 17.5%

  • Vs GIS

    In the last 3 years, Usana Health Sciences Inc. has experienced a drawdown of -54.5%, however General Mills, Inc. resisted the overall trend and outperformed by 38.6%

Institutional Holdings

  • BlackRock Inc

    9.54%
  • Vanguard Group Inc

    8.30%
  • Renaissance Technologies Corp

    6.42%
  • Pzena Investment Management, LLC

    4.12%
  • Dimensional Fund Advisors, Inc.

    3.57%
  • State Street Corporation

    2.32%

Company Information

usana health sciences’ mission is to develop and provide the highest quality, science-based health products, distributed internationally through network marketing, creating a rewarding financial opportunity for our independent associates, shareholders, and employees. we’ve got history. not baggage. we’ve been around since 1992, so we’re experienced (we’ve heard that’s a plus). and we look great for our age. plus, we have substance to go along with our great looks. we’ve got top-notch manufacturing facilities, our own scientists and research and development team, and the highest standards for our nutritional products. we have an award-winning compensation plan and award-winning products. we don’t like to brag, but we come pretty highly recommended. that’s because we got off on the right foot. we were founded by a scientist—not a corporate suit. usana’s founder, myron wentz, is an internationally recognized microbiologist, immunologist, and pioneer in infectious disease diagnosis. but su

Organization
Usana Health Sciences Inc.
Employees
1800
CEO
Mr. Kevin G. Guest
Industry
Consumer Non-Durables

FAQs